Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132442 · ClinicalTrials.gov registry record · Phase 3
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
A Phase 3 study of Type 2 Diabetes and Vitamin D Deficiency, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02132442 is a Phase 3 study of Type 2 Diabetes and Vitamin D Deficiency that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 12 participants, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02132442, a Phase 3 study of Type 2 Diabetes and Vitamin D Deficiency, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to study the effect of vitamin D intake on the severity of fatty liver and poor glucose control in patients with type 2 diabetes and fatty liver disease.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Ergocalciferol, placebo
Study Locations (1)
Massachusetts
- University of Massachusetts Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02132442
The ClinicalTrials.gov registry entry for NCT02132442 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Ergocalciferol, placebo is the first listed.
NCT02132442 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02132442 about?
NCT02132442 is a clinical study titled "Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes". This study is designed to study the effect of vitamin D intake on the severity of fatty liver and poor glucose control in patients with type 2 diabetes and fatty liver disease.
What is the current status of trial NCT02132442?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2014-03. Estimated completion is 2016-10.
What conditions does trial NCT02132442 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Vitamin D Deficiency, Nonalcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT02132442?
The interventions under investigation include: Ergocalciferol, placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02132442?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02132442 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.